AZN

AstraZeneca
NYSE

Real-time Quotes | Nasdaq Last Sale

55.95
-0.13
-0.23%
After Hours: 56.21 +0.26 +0.46% 19:54 08/05 EDT
OPEN
56.43
PREV CLOSE
56.08
HIGH
56.57
LOW
55.82
VOLUME
3.27M
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
36.15
MARKET CAP
146.84B
P/E (TTM)
68.39
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AZN stock price target is 56.65 with a high estimate of 60.00 and a low estimate of 50.00.

EPS

AZN News

More
Moderna Earnings: Coronavirus Vaccine Maker Tops Views
Investor's Business Daily · 3h ago
Moderna's stock rallies as it moves forward with enrolling its Phase 3 COVID-19 vaccine trial
MarketWatch · 11h ago
Novavax up 17% on early-stage COVID-19 vaccine data
Seeking Alpha - Article · 13h ago
Phase 3 Trials And More: Any COVID-19 Data Is Good Data, Even If It's Bad
Seeking Alpha - Article · 1d ago
Charts Suggest It's Time to Invest in European Equities
Investopedia · 1d ago
Flu shot makers plan to supply record numbers of vaccine doses amid Covid-19 pandemic
Public health officials are making an even bigger push for flu vaccination this year to try to reduce hospitalizations from the disease amid the Covid-19 pandemic. Flu shot makers plan to supply record numbers of vaccine doses.
CNBC.com · 1d ago
U.S. government begins two trials testing Eli Lilly's coronavirus antibody drug
The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera.
CNBC.com · 1d ago
Emergent BioSolutions Inc. -- Moody's assigns Ba2 CFR to Emergent BioSolutions
Moody's · 1d ago

Industry

Pharmaceuticals
+0.32%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Symbol
Price
%Change

About AZN

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
More

Webull offers kinds of AstraZeneca plc (ADR) stock information, including NYSE:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.